79.31
price down icon0.81%   -0.65
pre-market  Vorhandelsmarkt:  79.47   0.16   +0.20%
loading

Merck Co Inc Aktie (MRK) Neueste Nachrichten

pulisher
Jul 21, 2025

Lobbying Update: $4,980,000 of MERCK & CO INC lobbying was just disclosed - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

Merck & Co., Inc. (MRK) Breaks Ground on $1B Biologics Hub to Boost KEYTRUDA Production - Insider Monkey

Jul 21, 2025
pulisher
Jul 21, 2025

Merck Commits to Veeva Vault CRM – Company Announcement - Financial Times

Jul 21, 2025
pulisher
Jul 20, 2025

Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead? - The Motley Fool

Jul 20, 2025
pulisher
Jul 19, 2025

MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire

Jul 19, 2025
pulisher
Jul 18, 2025

Peter Lynch's Investment Strategy: A Detailed Analysis of MERCK & CO INC (MRK) - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Merck’s (MRK) Dividend History: A Track Record of Consistency - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Jefferies Raises Merck (MRK) Price Target, Maintains Buy Rating - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Merck KGaA gets EU nod for Ezmekly (MRK:NYSE) - Seeking Alpha

Jul 18, 2025
pulisher
Jul 18, 2025

Livestock Identification Company Evaluation Report 2025 | Merck, Shearwell, Datamars Drive Innovations with Comprehensive Tagging and Tracking Solutions - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

Morgan Stanley Lowered the Firm’s PT on Merck & Co (MRK), Kept a Hold Rating - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Merck’s SWOT analysis: stock faces keytruda patent cliff, gardasil challenges - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Merck’s SWOT analysis: stock faces keytruda patent cliff, gardasil challenges By Investing.com - Investing.com UK

Jul 18, 2025
pulisher
Jul 16, 2025

Why Merck Is A Better Dividend Stock Than Gilead Sciences (NYSE:MRK) - Seeking Alpha

Jul 16, 2025
pulisher
Jul 15, 2025

Merck & Co., Inc. (MRK) Is Unlikely To Face Antitrust Action For Verona Deal, Says Jim Cramer - MSN

Jul 15, 2025
pulisher
Jul 15, 2025

Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention - Yahoo Finance

Jul 15, 2025
pulisher
Jul 14, 2025

The Zacks Analyst Blog Highlights Microsoft, Alibaba Group, Merck, Monarch Cement and Team - Yahoo Finance

Jul 14, 2025
pulisher
Jul 14, 2025

Merck & Co advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Merck to Start Phase 3 Trials of MK-8527 for HIV Prevention - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill - Business Wire

Jul 14, 2025
pulisher
Jul 13, 2025

Verona Pharma (VRNA) Opinions on Merck Acquisition News - Quiver Quantitative

Jul 13, 2025
pulisher
Jul 12, 2025

Merck & Co., Inc. (MRK)’s CEO Thinks He’s Got $50 Billion Of New Drugs, Says Jim Cramer - MSN

Jul 12, 2025
pulisher
Jul 12, 2025

UBS Affirms Merck & Co’s (MRK) ‘Buy’ Rating on HPV Vaccine Prospects - MSN

Jul 12, 2025
pulisher
Jul 12, 2025

Key deals this week: Meta, Boyd Gaming, Merck, Sandstorm Gold, Capgemini and more - Seeking Alpha

Jul 12, 2025
pulisher
Jul 12, 2025

Verona Pharma plc (VRNA): Jim Cramer Approves The Merck Acquisition - Yahoo Finance

Jul 12, 2025
pulisher
Jul 11, 2025

Success Tricking FDA Shouldn't Protect Merck, Justices Told - Law360

Jul 11, 2025
pulisher
Jul 11, 2025

Merck to Acquire Verona Pharma in $10B Bid - USA Herald

Jul 11, 2025
pulisher
Jul 11, 2025

Top Analyst Reports for Microsoft, Alibaba & Merck - TradingView

Jul 11, 2025
pulisher
Jul 11, 2025

FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill - Yahoo Finance

Jul 11, 2025
pulisher
Jul 11, 2025

With Verona deal, Merck wagers on strength of lung drug’s patents - BioPharma Dive

Jul 11, 2025
pulisher
Jul 11, 2025

Merck: Jefferies raises TP after Verona acquisition - MarketScreener

Jul 11, 2025
pulisher
Jul 11, 2025

Jefferies Adjusts Merck & Co.'s Price Target to $141 From $138, Keeps Buy Rating - MarketScreener

Jul 11, 2025
pulisher
Jul 11, 2025

Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock? - Nasdaq

Jul 11, 2025
pulisher
Jul 10, 2025

Merck Animal Health gets FDA nod for Bravecto Quantum (MRK:NYSE) - Seeking Alpha

Jul 10, 2025
pulisher
Jul 10, 2025

Merck Animal Health's Flea-and-Tick Treatment Approved in U.S. - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health - Business Wire

Jul 10, 2025
pulisher
Jul 10, 2025

Merck & Co. Remains In The BD Game After Verona Takeout - insights.citeline.com

Jul 10, 2025
pulisher
Jul 10, 2025

Merck Acquires Verona Pharma for $10B to Support Portfolio with COPD Drug Ohtuvayre Ahead of Keytruda Patent Expiration - Insider Monkey

Jul 10, 2025
pulisher
Jul 10, 2025

Merck's doravirine/islatravir under FDA review for HIV (MRK:NYSE) - Seeking Alpha

Jul 10, 2025
pulisher
Jul 10, 2025

U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection - Business Wire

Jul 10, 2025
pulisher
Jul 10, 2025

Merck to acquire UK drugmaker Verona Pharma for $10bn - World Pharmaceutical Frontiers

Jul 10, 2025
pulisher
Jul 10, 2025

Foley Represents Verona Pharma in $10B Acquisition by Merck - Foley & Lardner LLP

Jul 10, 2025
pulisher
Jul 09, 2025

Merck (MRK) Rises Higher Than Market: Key Facts - Yahoo Finance

Jul 09, 2025
pulisher
Jul 09, 2025

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory - insights.citeline.com

Jul 09, 2025
pulisher
Jul 09, 2025

In a $10B deal, Merck buys cardio developer Verona - BioWorld MedTech

Jul 09, 2025
pulisher
Jul 09, 2025

Merck spends $10 billion for Verona, gaining access to its COPD medication - Jacksonville Journal-Courier

Jul 09, 2025
pulisher
Jul 09, 2025

Merck Buys Verona Pharma: A Good Deal, But M&A Spree Must Continue (NYSE:MRK) - Seeking Alpha

Jul 09, 2025
pulisher
Jul 09, 2025

Merck to buy Verona and its lung drug in $10B deal - BioPharma Dive

Jul 09, 2025
pulisher
Jul 09, 2025

Merck to Buy Verona Pharma in $10 Billion Deal - The Wall Street Journal

Jul 09, 2025
pulisher
Jul 09, 2025

Merck to acquire Verona Pharma for $10 billion - Reuters

Jul 09, 2025
pulisher
Jul 09, 2025

Verona Pharma Stock Jumps 20%. It’s Being Bought for $10 Billion by Merck. - Barron's

Jul 09, 2025
pulisher
Jul 09, 2025

Verona Pharma Stock Soars to All-Time High as Merck Buys Firm for $10B - Investopedia

Jul 09, 2025
pulisher
Jul 09, 2025

Freshfields Guides Merck's $10B Deal For Verona Pharma - Law360

Jul 09, 2025
pulisher
Jul 09, 2025

Merck to Buy Verona for $10 Billion as Patent Cliff Looms - Bloomberg.com

Jul 09, 2025
pulisher
Jul 09, 2025

Merck Faces Multiple Challenges: Will It Steer Through Successfully? - Yahoo Finance

Jul 09, 2025
pulisher
Jul 09, 2025

Merck Makes Big Respiratory Play With $10B Acquisition of Verona - BioSpace

Jul 09, 2025
pulisher
Jul 09, 2025

Transcript : Merck & Co., Inc., Verona Pharma plcM&A Call - MarketScreener

Jul 09, 2025
pulisher
Jul 09, 2025

Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck - Nasdaq

Jul 09, 2025
drug_manufacturers_general NVO
$64.92
price up icon 0.95%
$295.87
price up icon 0.38%
drug_manufacturers_general NVS
$114.14
price down icon 0.10%
drug_manufacturers_general PFE
$24.26
price down icon 0.86%
$108.28
price up icon 0.06%
Kapitalisierung:     |  Volumen (24h):